Welldoc, a leading digital health company revolutionizing chronic disease management, announced today its strategic partnership with Redox Inc., the leading interoperability platform for healthcare data exchange. The partnership will allow providers to receive and review insights about users of the BlueStar® digital health app for diabetes management directly within their EHR at the point of care. With a shared vision to improve health outcomes of patients and alleviate physician burden, Welldoc and Redox are positioned to optimize clinical decision support by making more patient data available in real time. This is critical for patients managing a chronic disease.
Akili Interactive today announced that results from the STARS-ADHD trial of AKL-T01, a digital therapeutic designed to improve attention in children with attention-deficit/hyperactivity disorder (ADHD) were published in The Lancet Digital Health journal. The publication represents the first presentation of complete results from the STARS-ADHD trial, a first-of-its-kind large, randomized, multi-center, controlled study of the company’s flagship technology and the first seminal trial in a series of recent and ongoing studies of the attentional treatment. Results show AKL-T01 improved both objective measures and parent observations of attention and functional impairments.
DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace.
Albertsons Companies is one of the largest retailers in the United States, with more than 2,000 grocery stores under well-known banners such as Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen and Carrs. Through more than 1,700 in-store pharmacies across the country, Albertsons services millions of patients each year.
New data from digital inhalers confirms that exposure to the air pollutant ozone is strongly linked to increased use of inhaled medications for asthma symptoms, according to a new study from CommonSpirit Health; Propeller Health; University of California, Berkeley; and University of California, San Francisco, published in Environment International.
Asthma is one of the most common chronic respiratory diseases in the United States, resulting in more than $82 billion a year in healthcare costs. In the Sacramento and San Joaquin Valleys of California, people have unusually high levels of asthma-related emergency department visits and hospitalizations. This prompted CommonSpirit to study environmental factors that could be worsening asthma symptoms for its patients.
Mental health has become a global epidemic, and employers are quickly becoming aware of how important it is to provide resources for workers who may be struggling.
“We’ve gone through an evolution from where mental health wasn’t being addressed at all within the workplace to a point today where there is a far higher level of awareness,” says Ken Cahill, CEO of SilverCloud Health, a digital mental health company. “But we have to move from that to providing an actionable plan and a solution within the workplace.”
MedRhythms, a Portland, Maine-based digital therapeutics company that uses sensors, software, and music to measure and improve walking, today announced the advancement of its pipeline in multiple sclerosis (MS) and Parkinson’s disease (PD). As part of this effort, MedRhythms has established MS and PD Scientific Advisory Boards that will provide guidance related to the Company’s clinical and research activities in these disease states. Additionally, MR-004, the Company’s pipeline product for walking rehabilitation in MS, will be studied at Cleveland Clinic in a pilot-scale randomized controlled trial to evaluate its safety and efficacy. This trial is made possible by a grant from the Consortium of Multiple Sclerosis Centers (CMSC).
The Digital Therapeutics Alliance (DTA) is pleased to welcome the following individuals to the DTA Board of Directors:
“When DTA launched in 2017, the conversation was focused on how digital therapeutics would be defined and work alongside other evidence-based therapies. Through the work of DTA’s Board and members, the conversation has evolved to: ‘How do these products address underserved populations and conditions? What clinical interventions and outcomes are delivered in real world settings? How is value achieved and quantified for patients, clinicians, and payors?’,” shared Megan Coder, DTA’s Executive Director.
Over the last two years, DTA released a series of foundational documents to differentiate digital therapeutics (DTx) from other products on the market and establish a level of rigor all DTx products should achieve. Publications include:
Individuals who are elected by DTA members to the Board of Directors serve two-year terms. In line with DTA’s 2020 priorities, the Alliance will launch two additional Work Groups and appoint Special Advisors to provide guidance related to strategic initiatives.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more please visit: www.dtxalliance.org.
Pear Therapeutics, Inc., the leader in Prescription Digital Therapeutics (PDTs), announced today that it has entered into agreements with multiple technology innovators, including Firsthand Technology, Inc., leading researchers from the Karolinska Institute in Sweden, Cincinnati Children’s Hospital Medical Center, Winterlight Labs, Inc., and NeuroLex Laboratories, Inc. These new agreements continue to bolster Pear’s PDT platform, by adding to its library of digital biomarkers, machine learning algorithms, and digital therapeutics.
Our industry-first Digital Health Formulary will allow employers and health plans to manage this fast-growing segment of health care while improving access for patients.
As more people turn to digital programs to help manage serious illnesses and take better control of their health, Express Scripts is making it easier to connect consumers with the apps, devices and digital therapeutics that work best for them.
In May, we announced we were developing the first-ever formulary for digital health. Since then, we have been building this industry changing platform, establishing a four-stage formulary review and selection protocol and reviewing hundreds of submissions from digital health developers.
The study, which was presented at the Meeting of the American College of Neuropsychopharmacology yesterday, found that patients using the technology improved their sustained attention compared to those in the control group.